Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Another Isis antisense compound to enter clinic

Feb. 7, 1997

Isis previews antisense anticancer program

Feb. 7, 1997

Follow-up data reported for Amelorad

Feb. 7, 1997

Merck describes improved chemotherapeutic agents

Feb. 7, 1997

Whole-body hyperthermia therapy enters clinic for new indication

Feb. 6, 1997

Sugen's TK antagonist enters phase II

Feb. 6, 1997

Antitumor prodrugs for ADEPT from Pharmachemie

Feb. 6, 1997

ChiRex and Cell Therapeutics sign supply agreement

Feb. 5, 1997

GeneMedicine IND approved

Feb. 4, 1997

Demeter receives funding for anticancer program

Feb. 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...